<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03111238</url>
  </required_header>
  <id_info>
    <org_study_id>REX-001-004</org_study_id>
    <nct_id>NCT03111238</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM</brief_title>
  <official_title>The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Rest Pain in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 4 and Diabetes Mellitus (DM): a Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ixaka Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Andalusian Network for Design and Translation of Advanced Therapies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ixaka Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial&#xD;
      conducted in subjects with DM and CLI Rutherford Category 4. Minimisation will be used to&#xD;
      assign eligible subjects in a 2:1 ratio to receive a single intra-arterial administration of&#xD;
      REX-001 or matching placebo into the index limb.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped due to inactivity&#xD;
  </why_stopped>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete relief of ischemic rest pain without developing ischemic lesions on the index leg.</measure>
    <time_frame>The primary endpoint for this trial will be assessed at 12 months.</time_frame>
    <description>Change in Rutherford classification from CLI Category 4 to Category 3 or lower 12 months after administration of REX-001 or placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Peripheral Arterial Disease (PAD)</condition>
  <condition>Diabetes Mellitus (DM)</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Critical Limb Ischemia (CLI)</condition>
  <arm_group>
    <arm_group_label>REX-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REX-001 is a cell suspension of autologous BM-MNCs composed of several mature cell types.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The final formulation of the placebo will be a diluted suspension of red blood cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REX-001</intervention_name>
    <description>REX-001 is administered through an intra-arterial catheter.</description>
    <arm_group_label>REX-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered through an intra-arterial catheter.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥ 18 to ≤ 85 years.&#xD;
&#xD;
          2. Diagnosis of Type I or II DM, established more than one year ago.&#xD;
&#xD;
          3. Glycosylated hemoglobin (HbA1c) &lt; 9%.&#xD;
&#xD;
          4. Subjects with poor or no (surgical or endovascular) revascularization option&#xD;
             classified as CLI Rutherford Category 4. The blood circulation in these subjects must&#xD;
             be compromised at screening, defined as:&#xD;
&#xD;
               -  Ankle systolic pressure &lt; 50 mm Hg, or&#xD;
&#xD;
               -  Toe systolic pressure &lt; 30 mm Hg, or&#xD;
&#xD;
               -  TcpO2 &lt; 30 mm Hg, and&#xD;
&#xD;
               -  Flat or barely pulsatile ankle or metatarsal PVR&#xD;
&#xD;
          5. In the opinion of the Investigator, the subject is controlled on medical therapy&#xD;
             indicated for CLI (unless there is a documented contraindication or intolerance) and&#xD;
             pain management is optimized.&#xD;
&#xD;
          6. Women of childbearing potential (i.e., fertile, following menarche and until becoming&#xD;
             post-menopausal unless permanently sterile) must have a negative pregnancy test at&#xD;
             screening. Men and women who are sexually active shall use effective contraceptive&#xD;
             methods for the duration of their participation in this study if the partner of the&#xD;
             male participant, or if the female participant is of childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Advanced CLI defined as presence of major tissue loss as significant&#xD;
             ulceration/gangrene proximal to the metatarsal heads (CLI Rutherford Category 6).&#xD;
             Significant ulceration/gangrene means any ulceration that extends beyond the&#xD;
             subcutaneous tissue layer, or any gangrene or tissue necrosis proximal to the&#xD;
             metatarsal heads.&#xD;
&#xD;
          2. CLI Rutherford Category 5.&#xD;
&#xD;
          3. Uncontrolled or untreated proliferative retinopathy.&#xD;
&#xD;
          4. Failed surgical or endovascular revascularization on the index leg within 10 days&#xD;
             after the procedure.&#xD;
&#xD;
          5. Subjects in whom arterial insufficiency in the lower extremity is the result of acute&#xD;
             limb ischemia or an immunological or inflammatory or non-atherosclerotic disorder&#xD;
             (e.g., thromboangiitis obliterans (Buerger's Disease), systemic sclerosis (both&#xD;
             limited and diffuse forms).&#xD;
&#xD;
          6. Clinical evidence of invasive infection on index leg defined as major tissue loss at&#xD;
             the mid-foot or heel involving tendon and/or bone, and/or when intravenous antibiotics&#xD;
             are required to treat the infection according to the Investigator.&#xD;
&#xD;
          7. At screening, the presence of only neuropathic ulcers on the index leg.&#xD;
&#xD;
          8. Amputation at or above the talus on the index leg.&#xD;
&#xD;
          9. Planned major amputation within the first month after randomization.&#xD;
&#xD;
         10. On the index leg, use of concomitant wound treatments not currently approved for&#xD;
             ischemic wound-healing within 30 days prior to screening or plans to initiate new,&#xD;
             nonstandard-of-care treatments to the index leg during the trial.&#xD;
&#xD;
         11. Blood clotting disorder not caused by medication (e.g., thrombophilia).&#xD;
&#xD;
         12. Severe hypertension according to the Joint National Committee on Prevention,&#xD;
             Detection, Evaluation, and Treatment of High Blood Pressure.&#xD;
&#xD;
         13. A platelet count &lt; 50,000/ μL.&#xD;
&#xD;
         14. International normalised ratio (INR) &gt; 1.5. For patients on anticoagulant medication&#xD;
             an INR &gt; 1.5 is allowed, provided that the Investigator and the haematologist consider&#xD;
             the patient eligible to collect BM.&#xD;
&#xD;
         15. Evidence of moderate to severe hepatocellular dysfunction according to the treating&#xD;
             physician.&#xD;
&#xD;
         16. Positive test for human immunodeficiency virus 1 (HIV 1), HIV 2, hepatitis B virus&#xD;
             (HBV), hepatitis C virus (HCV) or Treponema pallidum.&#xD;
&#xD;
         17. Subjects who may not be healthy enough to successfully complete all protocol&#xD;
             requirements including BM collection, or who are not expected to survive more than 12&#xD;
             months, or in whom results may be particularly difficult to assess, as assessed by the&#xD;
             Investigator.&#xD;
&#xD;
         18. Subjects who participate in another clinical interventional trial.&#xD;
&#xD;
         19. Subjects who have been treated with experimental medication within 30 days of&#xD;
             screening.&#xD;
&#xD;
         20. Subjects who were treated with other cell therapies for CLI within the last 12 months&#xD;
             preceding the screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilbert Wagener, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ixaka Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fakultní nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitkovicka nemocnice a. s. Vaskularni centrum</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Goethe-Universität Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem, PTE-KK I. sz Belgyógyászati Klinika</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de São João</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First site: Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Granada, Hospital del Campus de la Salud</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autologous</keyword>
  <keyword>Bone Marrow-derived Mononuclear Cells (BM-MNCs)</keyword>
  <keyword>Advanced Therapy Medicinal Product (ATMP)</keyword>
  <keyword>Tissue-engineered Medicinal Product</keyword>
  <keyword>Revascularization</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Vasculogenesis</keyword>
  <keyword>Arteriogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

